A Connexin40 Mutation Associated With a Malignant Variant of Progressive Familial Heart Block Type I
Naomasa Makita(National Cerebral and Cardiovascular Center), Mario Delmar(New York University), Wataru Shimizu(Nippon Medical School Hospital), Connie R. Bezzina(Amsterdam Neuroscience), Naoki Mochizuki(National Cerebral and Cardiovascular Center), Minoru Horie(Nagahama City Hospital), Jean‐Jacques Schott(Centre National de la Recherche Scientifique), Shigetomo Fukuhara(Institute for Advanced Medical Research), Halina Chkourko(Nagasaki University), Dan M. Roden(Garvan Institute of Medical Research), Hiroshi Watanabe(Nagasaki University), Alban‐Elouen Baruteau(Centre National de la Recherche Scientifique), Hervé Le Marec(Centre National de la Recherche Scientifique), Naokata Sumitomo(Saitama Medical University), Estelle Baron(Centre National de la Recherche Scientifique), Takeru Makiyama(Kyoto University), Can Hasdemir(Ege University), Nobuhisa Hagiwara(Tokyo Women's Medical University), Akiko Seki(Nagasaki University), Vincent Probst(Centre National de la Recherche Scientifique), Hideo Mugishima(Children's Oncology Group), Arthur A.M. Wilde(Amsterdam Neuroscience)
Cited by 69
Related Papers
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
|European Heart Journal|2018|2.1k
Genotype-Phenotype Correlation in the Long-QT Syndrome
|Circulation|2001|1.8k